KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Prepaid Assets (2016 - 2025)

Alnylam Pharmaceuticals (ALNY) has disclosed Prepaid Assets for 16 consecutive years, with $281.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Prepaid Assets rose 141.01% year-over-year to $281.9 million, compared with a TTM value of $281.9 million through Dec 2025, up 141.01%, and an annual FY2025 reading of $281.9 million, up 141.01% over the prior year.
  • Prepaid Assets was $281.9 million for Q4 2025 at Alnylam Pharmaceuticals, up from $188.0 million in the prior quarter.
  • Across five years, Prepaid Assets topped out at $281.9 million in Q4 2025 and bottomed at $76.0 million in Q1 2021.
  • Average Prepaid Assets over 5 years is $140.4 million, with a median of $131.3 million recorded in 2022.
  • Peak annual rise in Prepaid Assets hit 141.01% in 2025, while the deepest fall reached 24.53% in 2025.
  • Year by year, Prepaid Assets stood at $88.1 million in 2021, then soared by 50.91% to $132.9 million in 2022, then decreased by 4.92% to $126.4 million in 2023, then dropped by 7.45% to $117.0 million in 2024, then skyrocketed by 141.01% to $281.9 million in 2025.
  • Business Quant data shows Prepaid Assets for ALNY at $281.9 million in Q4 2025, $188.0 million in Q3 2025, and $147.3 million in Q2 2025.